Jammu Journal

Fragile X Syndrome (FXS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Fragile X Syndrome (FXS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

July 02
19:25 2021
Fragile X Syndrome (FXS) Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hypermethylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.

At birth FXS neonates often exhibit no clinical signs of FXS with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood FXS, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. The behavioral phenotype of FXS includes significant anxiety, attention deficit hyperactivity disorder (ADHD), and hyperarousal to sensory stimuli.

There is no single treatment for FXS, but some treatments help minimize the symptoms of the condition. The treatment regimen of FXS includes the use of stimulants, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and alpha agonists.

The market is expected to grow by the factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide are anticipated to expand the market with more penetration in the 7MM markets.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market

The Fragile X Syndrome (FXS) Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Fragile X Syndrome (FXS) market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Fragile X Syndrome (FXS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


Fragile X Syndrome (FXS) Market

Fragile X Syndrome (FXS) Market Key Facts

  • The total diagnosed prevalent population of Fragile X Syndrome in the 7MM was estimated to be around 120,177 in 2020.

  • Among the European 5 countries, Germany had the highest prevalent population of Fragile X Syndrome (FXS), followed by France and the UK. On the other hand, Spain had the lowest prevalent population of Fragile X Syndrome (FXS)

  • The most prevalent cases of Fragile X Syndrome (FXS) were recorded in the United States.

  • Japan is estimated to have 12,836 cases of Fragile X Syndrome in 2020, which is expected to increase in the forecast period (2021-2030).

Key Benefits of Fragile X Syndrome (FXS) Market Report

  • Fragile X Syndrome (FXS) market report provides an in-depth analysis of Fragile X Syndrome (FXS) Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Fragile X Syndrome (FXS) Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Fragile X Syndrome (FXS) current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Fragile X Syndrome (FXS) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Fragile X Syndrome (FXS) Market 

The market size of Fragile X Syndrome (FXS) is anticipated to increase during the study period owing to the increasing prevalent population of Fragile X Syndrome (FXS) patients in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Fragile X Syndrome (FXS) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Fragile X Syndrome (FXS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Fragile X Syndrome (FXS) Therapeutics Market Assessment

Fragile X Syndrome (FXS) Epidemiology

The epidemiology section covers insights about the historical and current Fragile X Syndrome (FXS) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Fragile X Syndrome (FXS) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome (FXS) market or expected to get launched in the market during the study period. The analysis covers Fragile X Syndrome (FXS) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Fragile X Syndrome (FXS) Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Fragile X Syndrome (FXS) market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Fragile X Syndrome (FXS) emerging therapies.

Fragile X Syndrome (FXS) Companies

  • Marinus Pharmaceuticals

  • Alcobra Ltd./Arcturus Therapeutics

  • Ovid Therapeutics

  • Neuren Pharmaceuticals

  • Tetra Therapeutics

  • Confluence Pharmaceuticals

  • Zynerba Pharmaceuticals

And many others

Fragile X Syndrome (FXS) Therapies covered in the report include:

  • Zygel (Cannabidiol/ZYN002)

  • Acamprosate

  • BPN14770

  • Trofinetide

  • OV101 (gaboxadol)

  • Metadoxine (MG01CI)

  • Ganaxolone

And many more. 

The launch of the new therapies is expected in the forecast period (2021–2030). Among these, some are in late clinical stages of development, while others are in mid-stage clinical development, have shown promising results.

Table of Content

1. Key Insights

2. Executive Summary 

3. Fragile X Syndrome (FXS) Competitive Intelligence Analysis

4. Fragile X Syndrome (FXS) Market Overview at a Glance

5. Fragile X Syndrome (FXS) Disease Background and Overview

6. Fragile X Syndrome (FXS) Patient Journey

7. Fragile X Syndrome (FXS) Epidemiology and Patient Population

8. Fragile X Syndrome (FXS) Treatment Algorithm, Current Treatment, and Medical Practices

9. Fragile X Syndrome (FXS) Unmet Needs

10. Key Endpoints of Fragile X Syndrome (FXS) Treatment

11. Fragile X Syndrome (FXS) Marketed Products

12. Fragile X Syndrome (FXS) Emerging Therapies

13. Fragile X Syndrome (FXS) Seven Major Market Analysis

14. Attribute Analysis

15. Fragile X Syndrome (FXS) Market Outlook (7 major markets)

16. Fragile X Syndrome (FXS) Access and Reimbursement Overview

17. KOL Views on the Fragile X Syndrome (FXS) Market.

18. Fragile X Syndrome (FXS) Market Drivers

19. Fragile X Syndrome (FXS) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market

Latest Reports By DelveInsight
Fragile X Syndrome Pipeline Insights
Fragile X Syndrome Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Fragile X Syndrome market.

Peripheral Vascular Devices Market
DelveInsight’s ‘Peripheral Vascular Devices Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Peripheral Vascular Devices Market and the historical and forecasted Peripheral Vascular Devices market trends in the US, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/